Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq to Suspend Trading of BG Medicine's Stock

NEW YORK (GenomeWeb) – BG Medicine today announced that its stock will be suspended from trading on the Nasdaq effective Sept. 16. 

Its shares will begin trading on that day on the OTC Markets OTCQB market under ticker symbol "BGMD." 

BG Medicine said that Nasdaq notified it on Monday of the suspension resulting from the firm's continuing non-compliance with a listing requirement calling for a minimum $2.5 million in stockholders' equity or a market capitalization of at least $35 million. The company was warned by Nasdaq of its listing deficiency in November 2014.

BG Medicine had until Sept. 10 to remedy its listing deficiency. The firm said that it understands that its stock will be delisted from the Nasdaq "after all applicable review and appeal periods have lapsed."  

In afternoon trading today, BG Medicine's shares were down 24 percent at $.49. 

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.